glp 1 approved for nash Why are GLP-1 agonists being used to treat patients with nonalcoholic fatty liver disease? Current and future pharmacological therapies

Pushing volume too aggressively before the body adapts raises injury risk

And higher blood sugars tend to be associated with a higher risk of developing diabetic retinopathy

Perhaps the most important agenda item is in discussion on whether to keep this just an Ozempic case or to include other manufacturers such as those who made Rybelsus, Wegovy, Trulicity, and Mounjaro

Nausea (41%), diarrhea (23%), vomiting (20%), and constipation (18%) are the most frequently reported

GLP-1 medications carry a boxed warning regarding the risk of thyroid cancer, specifically medullary thyroid carcinoma (MTC)

Nature 424 : 561565 Lee TH, Kim SU, Yu SL, Kim SH, Park do S, Moon HB, Dho SH, Kwon KS, Kwon HJ, Han YH, Jeong S, Kang SW, Shin HS, Lee KK, Rhee SG and Yu DY (2003) Peroxiredoxin II is essential for sustaining life span of erythrocytes in mice